Neutropenia as a prognostic factor and safety of second‑line therapy with S‑1 for advanced or recurrent pancreatic cancer

  • Authors:
    • Makiko Ikagawa
    • Michio Kimura
    • Mina Iwai
    • Eiseki Usami
    • Tomoaki Yoshimura
    • Kimio Yasuda
  • View Affiliations

  • Published online on: June 24, 2016     https://doi.org/10.3892/mco.2016.940
  • Pages: 283-288
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of this retrospective study was to investigate the safety of S‑1 as second‑line therapy and to evaluate the association between neutropenia occurring during first‑line gemcitabine (GEM) therapy and survival for advanced or recurrent pancreatic cancer (APC). Between January, 2010 and December, 2014, 123 APC patients received chemotherapy at the Ogaki Municipal Hospital (Ogaki, Japan). Of those, 37 received GEM as first‑line and S‑1 as a second‑line therapy (GEM→S‑1 group). A further 60 patients received GEM as first‑line therapy, but did not receive second‑line therapy (GEM group). The median overall survival in the GEM→S‑1 (n=37) and GEM (n=60) groups was 323 days [95% confidence interval (CI): 138‑218.9 days] and 172 days (95% CI: 105‑184.4 days), respectively (P=0.0004). The median overall survival in the mild (grade ≤2; n=63) and severe (grade ≥3; n=34) neutropenia groups was 178 days (95% CI: 182‑275 days) and 330 days (95% CI: 297‑514 days), respectively (log‑rank test, P=0.0023). The severe non‑haematological toxicities associated with S‑1 as second‑line therapy were nausea (2.7%) and hand‑foot syndrome (2.7%). Second‑line S‑1 treatment was discontinued due to adverse events in 5.4% (2̸37) of the cases. In conclusion, neutropenia occurring during GEM therapy administered as first‑line treatment to APC patients was strongly associated with a better prognosis. S‑1 therapy as second‑line treatment was associated with a low incidence of severe adverse events and the patients were able to successfully continue treatment.
View Figures
View References

Related Articles

Journal Cover

September-2016
Volume 5 Issue 3

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ikagawa M, Kimura M, Iwai M, Usami E, Yoshimura T and Yasuda K: Neutropenia as a prognostic factor and safety of second‑line therapy with S‑1 for advanced or recurrent pancreatic cancer. Mol Clin Oncol 5: 283-288, 2016.
APA
Ikagawa, M., Kimura, M., Iwai, M., Usami, E., Yoshimura, T., & Yasuda, K. (2016). Neutropenia as a prognostic factor and safety of second‑line therapy with S‑1 for advanced or recurrent pancreatic cancer. Molecular and Clinical Oncology, 5, 283-288. https://doi.org/10.3892/mco.2016.940
MLA
Ikagawa, M., Kimura, M., Iwai, M., Usami, E., Yoshimura, T., Yasuda, K."Neutropenia as a prognostic factor and safety of second‑line therapy with S‑1 for advanced or recurrent pancreatic cancer". Molecular and Clinical Oncology 5.3 (2016): 283-288.
Chicago
Ikagawa, M., Kimura, M., Iwai, M., Usami, E., Yoshimura, T., Yasuda, K."Neutropenia as a prognostic factor and safety of second‑line therapy with S‑1 for advanced or recurrent pancreatic cancer". Molecular and Clinical Oncology 5, no. 3 (2016): 283-288. https://doi.org/10.3892/mco.2016.940